Campbell Shannon reported BDTX

Source

Document

SEC Form 4

Publisher

U.S. Securities and Exchange Commission (EDGAR)

Document ID

0002018966-26-000007

Machine-readable

Structured copy

Timestamps

Event (reported)

Jun 26, 2026

Published

Jun 29, 2026

Ingested by INSIDER

Nov 5, 03:50 UTC

Last re-read

Nov 5, 03:50 UTC

Extracted facts

Filer

Campbell Shannon

Role

Director

Transaction

Grant or awardAs filed: “A”

Asset

Black Diamond Therapeutics, Inc. — Stock Option (Right to Buy)

Ticker

BDTX

Shares

40.0K

Price per share

$0

Execution date (reported)

Jun 26, 2026

Owned after transaction

40.0K shares

Days from execution to publication

3

What this establishes

Campbell Shannon filed this Form 4 reporting a grant or award of BDTX on Jun 26, 2026. It became public on Jun 29, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

Extraction

Method

Form 4 XML

Confidence

1.00

Director

Campbell Shannoncik:0002018966

Issuer

Black Diamond Therapeutics, Inc.cik:0001701541

Revision history · 0

No field has changed since this record was first ingested.